MarketPulse

BEAM-302

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Beam Therapeutics' BEAM-302 Shows Promise in Alpha-1 Deficiency, Eyes Pivotal Trial

Beam Therapeutics reports positive Phase 1/2 data for BEAM-302 base editing therapy in alpha-1 antitrypsin deficiency, advancing toward pivotal development in late 2026.
BEAMclinical trialgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Beam Therapeutics to Unveil 2025 Results and Novel Liver Disease Program

Beam Therapeutics will discuss 2025 results and unveil a new liver disease program on February 24, 2026. The company also secured FDA alignment for accelerated approval of BEAM-302.
BEAMFDA approvalbase editing